Gritstone bio, Inc. financial data

Symbol
GRTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5959 Horton Street, Suite 300, Emeryville, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Gritstone Oncology, Inc. (to 4/23/2021)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 357 % -32.1%
Debt-to-equity 191 % +352%
Return On Equity -232 % -185%
Return On Assets -80 % -39.4%
Operating Margin -924 % -11.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98.1M shares +11.9%
Common Stock, Shares, Outstanding 98.1M shares +11.7%
Entity Public Float 174M USD +1.17%
Common Stock, Value, Issued 22K USD 0%
Weighted Average Number of Shares Outstanding, Basic 118M shares +3.47%
Weighted Average Number of Shares Outstanding, Diluted 118M shares +3.47%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 15.6M USD +2.94%
Research and Development Expense 130M USD +14.1%
General and Administrative Expense 30.5M USD +10%
Operating Income (Loss) -145M USD -14.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -145M USD -16.1%
Earnings Per Share, Basic -1.24 USD/shares +3.13%
Earnings Per Share, Diluted -1.24 USD/shares +3.13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.4M USD -10%
Marketable Securities, Current 3.91M USD -96%
Other Assets, Current 566K USD -22.3%
Assets, Current 51.9M USD -66.5%
Property, Plant and Equipment, Net 14.1M USD -30.8%
Operating Lease, Right-of-Use Asset 65.1M USD +317%
Assets 137M USD -34.6%
Accounts Payable, Current 7.25M USD +21.3%
Employee-related Liabilities, Current 4.34M USD -7.6%
Accrued Liabilities, Current 2.14M USD -31.4%
Contract with Customer, Liability, Current 1.29M USD -54.1%
Liabilities, Current 25.9M USD +4.86%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 56.1M USD +285%
Other Liabilities, Noncurrent 907K USD +261%
Liabilities 123M USD +78.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +98.1%
Retained Earnings (Accumulated Deficit) -700M USD -26.1%
Stockholders' Equity Attributable to Parent 14M USD -90.1%
Liabilities and Equity 137M USD -34.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.6M USD +16.3%
Net Cash Provided by (Used in) Financing Activities -379K USD -104%
Net Cash Provided by (Used in) Investing Activities 12.3M USD -41.9%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 98.1M shares +11.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.6M USD -111%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48.9M USD -10.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 858K USD +96.8%
Deferred Tax Assets, Valuation Allowance 189M USD +17.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 206M USD +24%
Operating Lease, Liability 63M USD +228%
Payments to Acquire Property, Plant, and Equipment 143K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -145M USD -16.4%
Lessee, Operating Lease, Liability, to be Paid 93.6M USD -9.01%
Property, Plant and Equipment, Gross 47.5M USD -4.15%
Operating Lease, Liability, Current 6.81M USD +47.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.4M USD -2.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.7M USD -14.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +25.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30.6M USD +578%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.5M USD +0.87%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +3.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 14.9M USD +121%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.7M USD +2.54%
Operating Lease, Payments 3.14M USD +50.1%
Additional Paid in Capital 714M USD +2.58%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 17M USD +238%
Share-based Payment Arrangement, Expense 12M USD -2.79%
Interest Expense 4.49M USD +118%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%